TessellateBio is a pioneering and fast-growing international biotechnology company, focusing on targets to address cancers that depend on synthetic lethality (SL) mechanisms.

They are looking to use their substantial funding to expand their innovative pipeline by exploiting additional targets for patient populations with unmet needs.